Related Experiment Video

Updated: Jun 17, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Mechanisms of T-cell inhibition: implications for cancer immunotherapy

Elizabeth A Mittendorf1, Padmanee Sharma

  • 1Department of Surgical Oncology, Unit 444, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. eamitten@mdanderson.org

Expert Review of Vaccines
|December 22, 2009
PubMed

Insights

Cancer vaccines often fail because regulatory mechanisms inhibit T-cell responses. Blocking these checkpoints may enhance anti-tumor immunity, improving cancer vaccine efficacy.

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Cancer vaccines aim to boost T-cell responses but show limited clinical efficacy.
  • Regulatory mechanisms, intrinsic and extrinsic to T cells, suppress vaccine-induced anti-tumor immunity.

Purpose of the Study:

  • To review regulatory mechanisms inhibiting effector T-cell responses against tumors.
  • To identify strategies for overcoming these inhibitory mechanisms to improve cancer vaccine effectiveness.

Main Methods:

  • Literature review of regulatory pathways impacting T-cell function in cancer.
  • Analysis of intrinsic and extrinsic regulatory checkpoints.
  • Identification of potential therapeutic targets for immune checkpoint blockade.

Main Results:

  • Several regulatory mechanisms significantly limit effector T-cell activity post-vaccination.
  • Immune checkpoints represent key targets for enhancing anti-tumor immune responses.
  • Circumventing regulatory pathways holds promise for augmenting vaccine efficacy.

Conclusions:

  • Understanding and targeting regulatory mechanisms are crucial for developing effective cancer vaccines.
  • Immune checkpoint blockade strategies offer a promising approach to enhance anti-tumor immunity.
  • Future research should focus on clinical strategies to overcome T-cell inhibition for improved cancer treatment.

More Related Videos

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...